Pipeline

Four programs, one platform

Four oral solid dose programs, all built on the same delivery technology.

Development pipeline

Where each program stands

ProgramDescriptionPathStage
BRY101 LNAD+ Medical food Phase 1b dose finding
BRY102 Neurodegenerative 505(b)(1) Preclinical
BRY103 Metabolic Modulator 505(b)(2) IND-enabling
BRY104 Oral peptide 505(b)(1) Preclinical
Approach

Two tracks, one technology

Our development programs advance through regulated pathways, from medical food to IND. Our commercial products generate revenue today through established distributor channels.

Near-term commercial activity funds longer-term clinical development. Every product and every candidate runs on the same platform.

See commercial products →
Programs

Program details

BRY101

Medical food

An oral NAD+ medical food in Phase 1b dose finding for wound healing. Preclinical data shows penetration into spinal cord tissue.

About BRY101 ↗

BRY102

505(b)(1)

An oral candidate for neurodegenerative disease on a 505(b)(1) path, in preclinical development.

About BRY102 ↗

BRY103

505(b)(2)

A metabolic modulator on a 505(b)(2) path, in IND-enabling studies.

About BRY103 ↗

BRY104

505(b)(1)

An oral peptide drug candidate in preclinical development.

About BRY104 ↗